PureTech Health PLC Director/PDMR Shareholding (7846R)
June 19 2018 - 2:01AM
UK Regulatory
TIDMPRTC
RNS Number : 7846R
PureTech Health PLC
19 June 2018
PureTech Health plc
Performance Share Plan
PureTech Health plc ("PureTech") announces that awards of
restricted share units ("RSUs") were granted by PureTech to certain
directors and other persons discharging managerial responsibilities
("PDMRs") pursuant to its Performance Share Plan ("PSP") on 15 June
2018. Each RSU entitles the holder to one ordinary share of par
value one pence each in PureTech ("Ordinary Share") upon the
satisfaction of performance vesting conditions which shall occur no
earlier than 1 January 2021.
The RSUs have been awarded to the directors and PDMRs in respect
of a total of 3,207,421 Ordinary Shares (representing approximately
1.14 per cent. of the issued ordinary share capital of PureTech) as
follows:
Director/PDMR Number of Ordinary Shares Percentage of issued
in respect of RSUs granted ordinary share capital
on 15 June 2018
Daphne Zohar 1,035,628 0.37%
Bharatt Chowrira 192,033 0.07%
Joesph Bolen 346,644 0.12%
Eric Elenko 346,644 0.12%
Joep Muijrers 593,185 0.21%
Stephen Muniz 346,644 0.12%
David Steinberg 346,644 0.12%
Vesting of the RSUs is subject to the satisfaction of
performance conditions based on the achievement of Total
Shareholder Return targets (50 per cent. of the awards), Relative
Shareholder Return targets (25 per cent. of the awards) and targets
based on strategic measures (25 per cent. of the awards), measured
over the three year period to 31 December 2020 ("Performance
Period"), as further described in the Directors' Remuneration
Report of PureTech's 2017 Annual Report and Accounts. The awards
will generally vest following the end of the Performance Period on
determination of the extent to which the performance conditions
have been satisfied. No award can vest before 1 January 2021. The
number of Ordinary Shares stated in the table above is the maximum
number that could be issued to each director or PDMR upon full
satisfaction of the performance conditions attaching to the RSUs.
The RSUs were granted for nil consideration. Following vesting,
each recipient will be required to make a payment of one pence per
Ordinary Share on settlement of the RSUs. All awards are subject to
recovery and withholding provisions.
About PureTech Health
PureTech Health (PRTC.L) is an advanced, clinical-stage
biopharmaceutical company developing novel medicines targeting
serious diseases that result from dysfunctions in the nervous,
immune, and gastrointestinal systems (brain-immune-gut or the "BIG"
axis), which together represent the adaptive human systems.
PureTech Health is at the forefront of understanding and addressing
the biological processes and crosstalk associated with the BIG
axis. By harnessing this emerging field of human biology, PureTech
Health is pioneering new categories of medicine with the potential
to have great impact on people with serious diseases. PureTech
Health is advancing a rich pipeline of innovative therapies that
includes two pivotal stage programmes, multiple human
proof-of-concept studies and a number of early clinical and
pre-clinical programmes. PureTech's research and development
pipeline has been advanced in collaboration with some of the
world's leading scientific experts, who along with PureTech's team
of biopharma pioneers, entrepreneurs and seasoned Board, identify,
invent, and clinically de-risk new medicines. With this experienced
team pursuing cutting edge science, PureTech Health is building the
biopharma company of the future focused on improving and extending
the lives of people with serious disease. For more information,
visit www.puretechhealth.com or connect with us on Twitter
@puretechh.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLVLLFVQFLBBX
(END) Dow Jones Newswires
June 19, 2018 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024